Skip to main content

Advertisement

SpringerLink
Log in

Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

Evidence for heterogeneity of several biological features of human malignant melanoma (Me) like morphology, cytogenetics, oncogenes activation, antigenic expression, metastatizing capacity and procoagulant activity are briefly reviewed in an attempt to distinguish findings related to primary vs. metastatic lesions. In our own studies monoclonal antibodies were used to study expression of MHC class I, class II products and of Me-associated antigens (MAA) on primary and metastatic Me cells. High expression of class I antigens was found in a high percentage of both primary and metastatic tumors, whereas DR and MAA showed a significant variation (from 3 to 90% of cells) in expression both in primary and in metastatic Me. When autologous cell-mediated immune responses were evaluated, it was found that Me cells from primary tumors but not those from lymph node metastases were able to stimulate autologous lymphocytes to proliferate and become cytotoxic for autologous Me.

Clonal analysis of cytotoxic lymphocytes was then carried out in order to see whether the lack of lymphocytes reactivity to metastatic cells was due to the absence or to a low frequency of cytotoxic cells in the unstimulated PBL. CTL clones cytotoxic for autologous Me (Auto-Me) cells were indeed isolated. Three classes of CTL clones were identified: 1) one which is cytotoxic for Auto-Me; 2) a second one which lyse Auto-Me and allogeneic Me; and 3) a third one which is cytotoxic for Auto-Me and allogeneic normal and neoplastic cells. Metastatic Me cells, however, had the ability to suppress the stimulation of autologous PBL by alloantigens or IL-2. This effect was dose-dependent and was not due to absorption of IL-2 by Me cells. Since it has been reported that Me cells express class II MHC antigens, we investigated whether there was any correlation between autologous immune responses and DR expression on Me cells. Autologous lymphocytes stimulation was found to occur only with DR+ Me cells from primary lesions, whereas metastatic cells, either DR+ or DR-, did not stimulate autologous PBL. Moreover, the suppressive effect of metastatic Me cells was associated with their expression of DR antigens. The modulation of DR antigens on Me cells by Interferon-gamma correlated positively with their suppressive capacity.

Thus, it appears that primary Me can behave differently from the metastatic one in their interactions with the immune system of autologous host. These findings suggest that DR antigens on Me cells may have an important role in the regulation of autologous immune responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fidler IJ, Hart IR: Biological diversity in metastatic neoplasms: Origins and implications. Science 217: 998–1003, 1982.

    Google Scholar 

  2. Weiss L: Random and nonrandom processes in metastasis, and metastatic inefficiency. Invasion and Metastasis 3: 193–207, 1983.

    Google Scholar 

  3. Heppner GH: Tumor heterogeneity. Cancer Res 44: 2259–2265, 1984.

    Google Scholar 

  4. Shapiro JR, Yung WA, Shapiro WR: Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41: 2344–2359, 1981.

    Google Scholar 

  5. Allegra JC, Barlock A, Huff K, Lippman E: Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer 45: 792–794, 1980.

    Google Scholar 

  6. Yung WA, Shapiro JR, Shapiro WR: Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. Cancer Res 42: 992–998, 1982.

    Google Scholar 

  7. Tanigawa N, Mizuno Y, Hashimura T, Honda K, Satomura K, Hisaka Y, Niwa O, Sugahara T, Yoshida O, Kern D, Morton DL: Comparison of drug sensitivity among tumor cells within a tumor between primary tumor and metastases, and between different metastases in the human tumorcolony-forming assay. Cancer Res 44: 2309–2312, 1984.

    Google Scholar 

  8. Albino AP, Lloyd OK, Houghton AN, Oettgen HF, Old LJ: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med 154: 1764–1778, 1981.

    Google Scholar 

  9. Horan Hand P, Nuti M, Colcher D, Schlom J: Monoclonal antibodies to tumor associated antigens define antigenic heterogeneity among human mammary carcinoma cell populations. Cancer Res 43: 728–735, 1983.

    Google Scholar 

  10. Natali PG, Viola M, Nicotra MR, Giacomini P, Bigotti A, Ferrone S: Antigenic heterogeneity of skin tumors of non-melanocytic origin: Analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst 71: 439–447, 1983.

    Google Scholar 

  11. Olsson L, Andreasen RB, Christensen B, Biberfeld P: Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells. J Exp Med 159: 537–550, 1984.

    Google Scholar 

  12. Albino AP, Le Strange R, Oliff AI, Forth ME, Old LJ: Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 308: 69–71, 1984.

    Google Scholar 

  13. Semple TU, Moore GE, Morgan RT, Woods LK, Quinn LA: Mutiple cell lines from patients with malignant melanoma: Morphology, karyology, and biochemical analysis. J Natl Cancer Inst 68: 365–380, 1982.

    Google Scholar 

  14. Elder DE, Ainsworth AM, Clark WE: The surgical pathology of cutaneous human melanoma, In: Clark WE, Goldman LE, Mastrangelo MA (eds) Clinical Oncology Monographs. Grune and Stratton, New York, 1979, pp 55–108.

    Google Scholar 

  15. Becher R, Gibas Z, Karakouis C, Sandberg AA: Nonrandom chrmosome channges in malignant melanoma. Cancer Res 43: 5010–5016, 1983.

    Google Scholar 

  16. Balaban G, Herlyn M, GuerryIV D, Bartolo R, Koprowski H, Clark WH, Nowell PC: Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 11: 429–439, 1984.

    Google Scholar 

  17. Herlyn M, Balaban G, Bennicelli J, Guerry IV D, Halaban R, Herlyn D, Elder DE, Maul G, Stepleski Z, Nowell PC, Clark WH, Koprowski H: Primary melanoma cells of the vertical growth phase have properties similar to metastatic cells. J Natl Cancer Inst (in press).

  18. Becher R, Gibas Z, Sandberg AA: Chromosome 6 in malignant melanoma. Cancer Genet Cytogenet 9: 173–175, 1983.

    Google Scholar 

  19. Wake N, Hreshchyshyn M, Piver S, Matsui S, Sandberg AA: Specific cytogenetic changes in ovarian cancer involving chromosome 6 and 14. Cancer Res 40: 4512–4518, 1980.

    Google Scholar 

  20. Kusyk C, Seski J, Medlin W, Edwards C: Progressive chromosome changes associated with different sites of one ovarian carcinoma. J Natl Cancer Inst 66: 1021–1025, 1981.

    Google Scholar 

  21. Barranco SC, Drewinko B, Humphrey RM: Differential response by human malanoma cells to 1, 3-bis(2-chloroethyl)-1-nitrosourea and bleomycin. Mut Res 19: 277–280, 1973.

    Google Scholar 

  22. Barranco SC, Ho D, Drewinko B, Romsdahl MH, Humphrey RM: Differential sensitivity of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res 32: 2733–2736, 1972.

    Google Scholar 

  23. Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Res 41: 3058–3064, 1981.

    Google Scholar 

  24. Vousden KH, Marshall CJ: Three different activated ras genes in mouse tumors: Evidence for oncogene activations during progression of a mouse lymphoma. EMBO J 3: 913–917, 1984.

    Google Scholar 

  25. Kerbel RS, Man MS, Dexter D: A model of human cancer metastases: Extensive spontaneous and artificical metastasis of a human pigmented melanoma and derived variant sublines in nude mice. J Natl Cancer Inst 72: 93–108, 1984.

    Google Scholar 

  26. Kozlowski MJ, Hart IR, Fidler IJ, Hanna N: A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 72: 913–917, 1984.

    Google Scholar 

  27. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62: 14–31, 1983.

    Google Scholar 

  28. Gordon SG, Cross BA: A factor X-activating cysteine protease from malignant tissue. J Clin Invest 67: 1665–1671, 1981.

    Google Scholar 

  29. Gordon SG, Franks JJ, Lewis BJ: Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 62: 773–776, 1979.

    Google Scholar 

  30. Gilbert LC, Gordon SG: Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants. Cancer Res 43: 536–540, 1983.

    Google Scholar 

  31. Poggi A, Colucci M, Delaini F, Semeraro N, Donati MB: Reduced procoagulant activity of Lewis lung carcinoma cells from mice treated with warfarin. Eur J Cancer 16: 1641–1642, 1980.

    Google Scholar 

  32. Poggi A, Mussoni L, Korublitt L, Ballabio E, deGaetano G, Donati MB: Warfarin enantiomers, anticoagulation and experimental tumor metastases. Lancet I 163–164, 1978.

    Google Scholar 

  33. Burchel SW, Martin JC, Imai K, Ferrone S, Warner NL: Heterogeneity of HLA-A, B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. Cancer Res 42: 4110–4116, 1982.

    Google Scholar 

  34. Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ, Mihm MC: Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J Immunol 129: 2808–2815, 1982.

    Google Scholar 

  35. Bruggen J, Sorg C: Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies. Cancer Immunol Immunother 15: 200–205, 1983.

    Google Scholar 

  36. Dippold WG, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: Definition of six new antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U.S.A. 77: 6114–6118, 1980.

    Google Scholar 

  37. Yeh MY, Hellstrom I, Hellstrom KE: Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody. J Immunol 126: 1312–1317, 1981.

    Google Scholar 

  38. Foa C, Rorsman CH, Rosenberg E: Differences in cell lines of human malignant melanocytes derived from the same tumors. J Invest Dermatol 66: 262–268, 1976.

    Google Scholar 

  39. Cillo C, Mach J-P, Schreyer M, Carrel S: Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis. Int J Cancer 34: 11–20, 1984.

    Google Scholar 

  40. Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, Ng AK, Giacomini P, Ferrone S: Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 130: 1462–1466, 1983.

    Google Scholar 

  41. Parmiani G, Pierotti MA: Generation of TSTA diversity. Looking for testable hypotheses. Cancer Immuno Immunother 14: 133–136, 1983.

    Google Scholar 

  42. Herberman RB: In vitro tests of cellular immunity in man. Invest Cell Pathol 1: 227–248, 1978.

    Google Scholar 

  43. Doherty PC, Zinkernagel RM: H-2 compatibility as required for T cell mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med 141: 502–507, 1975.

    Google Scholar 

  44. Old LJ: Cancer immunology: The search for specificity. Cancer Res 41: 361–375, 1981.

    Google Scholar 

  45. Vanky F, Klein E: Specificity of auto-tumour cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cancer 29: 547–553, 1982.

    Google Scholar 

  46. Vose BM, Bonnard GD: Human tumour antigens defined by cytolytic and proliferative responses of cultured lymphoid cells. Nature 296: 359–361, 1982.

    Google Scholar 

  47. Shiku H, Takahashi T, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med 144: 873–881, 1976.

    Google Scholar 

  48. Vose BM: Activation of lymphocyte antitumor response in man. Towards an understanding of effector cell heterogeneity? Cancer Immunol Immunother 17: 73–75, 1984.

    Google Scholar 

  49. Fossati G, Balsari A, Taramelli D, Sensi ML, Pellegris G, Nava M, Parmiani G: Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes. Cancer Immunol Immunother 14: 99–104, 1982.

    Google Scholar 

  50. Gately MK, Glaser M, Dick SJ, Mettetal RW, Kornblith PL: In vitro studies in the cell mediated immune response to human brain tumors. I. Requirement for third party stimulator lymphocytes in the induction of cell mediated cytotoxic response to allogeneic cultured gliomas. J Natl Cancer Inst 69: 1245–1254, 1982.

    Google Scholar 

  51. Guerry DIV, Alexander MA, Herlyn MF, Zehngebot LM, Michell KF, Zmijewski CM, Lusk EJ: HLA-DR histocom-patibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest 73: 267–271, 1984.

    Google Scholar 

  52. Fossati G, Taramelli D, Balsari A, Bogdanovich G, Andreola S, Parmiani G: Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer 33: 591–597, 1984.

    Google Scholar 

  53. Vanky F, Peterffy A, Book K, Willems J, Klein E, Klein G: Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course. II. Evaluation of 69 patients with lung carcinoma. Cancer Immunol Immunother 16: 17–22, 1983.

    Google Scholar 

  54. Schirrmacher V, Fogel M, Russmann E, Bosslet K, Altevogt P, Beck L: Antigenic variation in cancer metastasis: Immune escape versus immune control. Cancer Metastasis Rev 1: 241–274, 1982.

    Google Scholar 

  55. Pimm MV, Embleton MJ, Baldwin RW: Multiple antigenic specificities within primary 3-methylcholanthrene-induced rat sarcomas and metastases. Int J Cancer 25: 621–639, 1980.

    Google Scholar 

  56. Teale DM, Rees RC, Clark A, Potter CW: Properties of a herpes virus-transformed hamster cell line: Immunogenicity of sublines of high and low metastatic potential. Int J Cancer 33: 701–708, 1984.

    Google Scholar 

  57. Parmiani G, Balsari A, Fossati G, Taramelli D, Storchi I, Cascinelli N: Allostimulation generates killer lymphocytes against autologous human melanomas. In Reizenstein P, Chirigos M (eds), Proc 3rd Annual Meeting Clin Biol Evaluation Immunomodifiers, Cancer Treatment Symposia (in press), 1985.

  58. Zarling JM, Robins HI, Raich PC, Bach FH, Bach ML: Generation of cytotoxic lymphocytes to autologous human leukemia cells by sensitization of pooled allogeneic normal cells. Nature 274: 271–273, 1978.

    Google Scholar 

  59. Mazumder A, Grimm EA, Rosenberg SA: Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol Immunother 15: 1–10, 1983.

    Google Scholar 

  60. Hersey P, Bindon C, Edwards A, Murray E, Phillips G, McCarthy WH: Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin-2. Int J Cancer 28: 695–703, 1981.

    Google Scholar 

  61. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841, 1982.

    Google Scholar 

  62. Balsari A, Fossati G, Taramelli D, Nava M, Ravagnani F, Parmiani G: Inhibition of human melanoma growth in nude mice by autologous alloactivated peripheral blood lymphocytes. Tumori 70: 35–39, 1984.

    Google Scholar 

  63. Mukherji B, MacAlister IJ: Clonal analysis of cytotoxic T cell response against human melanoma. J Exp Med 158: 240–245, 1983.

    Google Scholar 

  64. Vose BM, White W: Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture. Clonal analysis of effector cells in cytotoxic and proliferative assays. Cancer Immunol Immunother 15: 227–236, 1983.

    Google Scholar 

  65. De Vries JE, Spits H: Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation and analysis to phenotype and specificity. J Immunol 132: 510–519, 1984.

    Google Scholar 

  66. Knuth A, Danowsky B, Oettgen HF, Old LJ: T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin-2 dependent T-cell cultures. Proc Natl Acad Sci U.S.A. 81: 3511–3515, 1984.

    Google Scholar 

  67. Moretta A, Pantaleo G, Mingari MG, Melioli G, Moretta L, Cerottini JC: Assignement of human natural killer (NK)-like cells to the T cell lineage. Single allospecific T cell clones lyse specific or NK-sensitive target cells via distinct recognition structures. Eur J Immunol 14: 121–125, 1984.

    Google Scholar 

  68. Berendt MJ, North RJ: T-cell mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151: 69–80, 1980.

    Google Scholar 

  69. Vose BM, Moore M: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer 24: 579–585, 1979.

    Google Scholar 

  70. Taramelli D, Fossati G, Balsari A, Marolda R, Parmiani G: The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int J Cancer 34: 797–806, 1984.

    Google Scholar 

  71. Gately MK, Glaser M, McCarron RM, Dick SJ, Dick MD, Mettetal RWJr, Kornblith PL: Mechanism by which human gliomas may escape cellular immune attack. Acta Neurochir 64: 175–197, 1982.

    Google Scholar 

  72. Akiyama A, Bean MA, Sadamoto K, Takahashi Y, Brankovan V: Suppression of the responsiveness of lymphocytes from cancer patients triggered by co-culture with autologous tumor-derived cells. J Immunol 131: 3085–3090, 1983.

    Google Scholar 

  73. Roth JA, Osborne BA, Ames RA: Immunoregulatory factors derived from human tumors. II. Partial purification and futher immunochemical characterization of a human sarcome-derived immunosuppressive factor expressing HLA-DR and immunoglobulin related determinants. J Immunol 130: 303–308, 1983.

    Google Scholar 

  74. Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WM: Inhibition of IL-2 production by factors released from tumor cells. J Immunol 131: 2837–2842, 1983.

    Google Scholar 

  75. Fontana A, Hengartner H, De Tribolet N, Weber E: Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2 mediated effects. J Immunol 132: 1837–1844, 1984.

    Google Scholar 

  76. Leonard WJ, Depper JN, Uchiyama T, Smith KA, Waldman TA, Greene WC: A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor: Partial characterization of the receptor. Nature 300: 267–268, 1982.

    Google Scholar 

  77. Unanue ER, Beller DI, Lu CY, Allen PM: Antigen presentation: Comments on its regulation and mechanism. J Immunol 132: 1–5, 1984.

    Google Scholar 

  78. Engleman EG, Benicke CJ, Charron DJ: Ia antigen on peripheral blood mononuclear leukocytes in man. II. Functional studies of HLA-DR positive T cell activated in mixed lymphocytes reactions. J Exp Med 152: 1145–1165, 1980.

    Google Scholar 

  79. Basham TY, Merigan TC: Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol 130: 1492–1494, 1983.

    Google Scholar 

  80. Wiman K, Curman B, Forsum U, Klareskog U, Malmnas T, Jemcund L, Rask L, Tragardh L, Peterson PA: Occurrence of Ia antigens on tissues of nonlymphoid origin. Nature 276: 711–713, 1978.

    Google Scholar 

  81. Natali PG, DeMartino C, Quaranta V, Bigotti A, Pellegrino MA, Ferrone S: Changes in Ia-like antigen expression on malignant human cells. Immunogenetics 12: 409–413, 1981.

    Google Scholar 

  82. Wong GHW, Bartlett PF, Clark-Lewis IAN, Battye F, Schrader JW: Inducible expression of H-2 and Ia antigens on brain cells. Nature 310: 688–691, 1984.

    Google Scholar 

  83. Pober JS, Collins T, Gimbrone MAJr, Cotran RS, Gitlin JD, Fiers W, Clayberger C, Krensky AM, Burakoff SJ, Reiss CS: Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature 305: 726–729, 1983.

    Google Scholar 

  84. Pollack MS, Chin-Louie J, Moshief RD: Functional characteristics and differential expression of class II DR, DS, and SB antigens on human melanoma cell lines. Human Immunol 9: 75–87, 1984.

    Google Scholar 

  85. Ramila G, Erb P: Accessory cell-dependent selection of specific T-cell functions. Nature 304: 442–445, 1983.

    Google Scholar 

  86. Klein J, Nagy ZA: Mhc restriction and Ir genes. Adv Cancer Res 37: 233–317, 1982.

    Google Scholar 

  87. Gonwa TA, Picker LJ, Raff HV, Goyert SM, Silver J, Stobo JD: Antigen-presenting capabilities of human monocytes correlates with their expression of HLA-DS, an Ia determinant distinct from HLA-DR. J Immunol 130: 706–711, 1982.

    Google Scholar 

  88. Corte G, Moretta A, Cosulich E, Ramarli D, Bargellesi A: A monoclonal anti-DC1 antibody selectively inhibits the generation of effector T cells mediating specific cytolytic activity. J Exp Med 156: 1539–1544, 1982.

    Google Scholar 

  89. Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ: Surface antigens of melanoma and melanocytes: Specificity of induction of Ia antigens by human γ interferon. J Exp Med 160: 255–269, 1984.

    Google Scholar 

  90. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ: Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 156: 1755–1766, 1982.

    Google Scholar 

  91. Vanky F, Klein E, Willems J: Ia-like antigens expressed on tumor cells do not contribute to the blastogenic response of autologous T cells. Cancer Immunol Immunother (in press).

  92. Kuntz MM, Innes JB, Weksler ME: Lymphocyte transformation induced by autologous or allogeneic non-T lymphocytes. J Exp Med 143: 1042–1054, 1976.

    Google Scholar 

  93. Indiveri F, Barabino A, Pierri I, Grifoni V: Human autologous mixed lymphocyte reactions. La Ricerca Clin Lab 13: 397–409, 1983.

    Google Scholar 

  94. Naor D: Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules. Cancer Immunol Immunother 16: 1–10, 1983.

    Google Scholar 

  95. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, MacKie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, Tomin R: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307: 913–916, 1982.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Oncology D, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

    Giorgio Parmiani, Giuseppe Fossati, Donatella Taramelli, Andrea Anichini & Carlo Gambacorti-Passerini

  2. Blood Transfusion Service, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

    Gianalfredo Sciorelli

  3. Division of Clinical Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

    Natale Cascinelli

  4. Institute of Medical Microbiology, University of Milan, Italy

    Andrea Balsari

Authors
  1. Giorgio Parmiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Fossati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donatella Taramelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea Anichini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Balsari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlo Gambacorti-Passerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gianalfredo Sciorelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Natale Cascinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parmiani, G., Fossati, G., Taramelli, D. et al. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer Metast Rev 4, 7–26 (1985). https://doi.org/10.1007/BF00047734

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00047734

Keywords

Search

Navigation